

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Hjerkind, KV; Ellingjord-Dale, M; Johansson, ALV; Aase, HS; Hoff, SR; Hofvind, S; Fagerheim, S; Dos-Santos-Silva, I; Ursin, G; (2018) Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program. *Cancer epidemiology, biomarkers & prevention*, 27 (9). pp. 1065-1074. ISSN 1055-9965 DOI: <https://doi.org/10.1158/1055-9965.EPI-18-0151>

Downloaded from: <http://researchonline.lshtm.ac.uk/4648290/>

DOI: <https://doi.org/10.1158/1055-9965.EPI-18-0151>

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program

Kirsti Vik Hjerkind^{1*}, Merete Ellingjord-Dale^{1,2}, Anna L V Johansson^{1,3}, Hildegunn Siv Aase⁴, Solveig Roth Hoff⁵, Solveig Hofvind^{1,6}, Siri Fagerheim⁷, Isabel dos-Santos-Silva⁸, Giske Ursin^{1,9,10}

¹ Cancer Registry of Norway, Institute of Population-based Cancer Research, Oslo, Norway

² Imperial College London, London, United Kingdom

³ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

⁴ Haukeland University Hospital, Bergen, Norway

⁵ Helse Møre og Romsdal HF, Ålesund, Norway

⁶ Oslo and Akershus University College of Applied Sciences, Oslo, Norway

⁷ Stavanger University Hospital, Stavanger, Norway

⁸ Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom

⁹ Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

¹⁰ Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

Running title Volumetric mammographic density and breast cancer exposures

Keywords volumetric mammographic density · breast cancer risk factors · menopausal status
· age · population-based screening

Additional information

Corresponding author:

Kirsti Vik Hjerkind

The Cancer Registry of Norway

Institute of population-based Cancer Research

Postbox 5313 Majorstuen

0304 Oslo

Norway

Email: kirsti.vik.hjerkind@kreftregisteret.no

Phone: +47 95 28 35 06

Fax: +47 22 45 13 70

The authors declare no potential conflict of interest.

Word count: 3926

Word count abstract: 249

Number of figures: 1

Number of tables: 5

Number of supplementary tables: 1

Financial support Norwegian Cancer Society, grant reference numbers 698320 and 161326

Abstract

Background: Volumetric mammographic density (VMD) measures can be obtained automatically, but it is not clear how these relate to breast cancer risk factors.

Materials and methods: The cohort consisted of 46 428 women (aged 49-71 years) who participated in BreastScreen Norway between 2007 and 2014 and had information on VMD and breast cancer risk factors. We estimated means of percent and absolute VMD associated with age, menopausal status, body mass index (BMI), and other factors.

Results: The associations between VMD and most breast cancer risk factors were modest, although highly significant. BMI was positively associated with absolute VMD, while inversely associated with percent VMD. Percent VMD was inversely associated with a five-years older age at screening in premenopausal and postmenopausal women (-0.18% versus -0.08% for percent VMD and -0.11 cm³ versus -0.03 cm³ for absolute VMD). This difference was largest among postmenopausal women with BMI<25 kg/m² (p for interaction with percent VMD<0.0001), never users of postmenopausal hormone therapy (p for interaction<0.0001), and premenopausal women with a family history of breast cancer (p for interaction with absolute VMD=0.054).

Conclusions: VMD is associated with several breast cancer risk factors, the strongest being BMI, where the direction of the association differ for percent and absolute VMD. The inverse association with age appears modified by menopausal status and other breast cancer risk factors.

Impact: Since VMD methods are becoming widely available in screening and clinical settings, the association between VMD measures and breast cancer risk factors should be investigated further in longitudinal studies.

Introduction

Mammographic density describes the relative amounts of radio-lucent fatty tissue versus radio-dense fibroglandular tissue in the breast (1). High density is a strong independent risk factor for breast cancer, with risk increasing with increasing density (2, 3). Women with a very high percentage of the breast occupied by dense tissue have a 4-6 fold increased risk of breast cancer compared to women who have predominately fatty breasts (3).

Traditionally, mammographic density assessment methods are based on a two-dimensional area-based projection of the breast. Such methods estimate area-based absolute density (i.e. the area occupied by dense tissue in cm^2) as well as percent density (i.e. the percentage of the total breast area occupied by dense tissue). Although the latter is the most frequently used area-based measure of mammographic density, both percent density and absolute density have been shown to be strong risk factors for breast cancer (4-9). The breast imaging reporting and data system (BI-RADS) is a commonly used ordinal density scale which provides a standardized classification for mammographic density (10).

Several automated methods have been developed for assessment of volumetric mammographic density (VMD) on digital images during the last decade. These methods assess the breast volume by multiplying the breast area on a two-dimensional mammogram by the compressed thickness of the breast. They determine the amount of dense tissue in the breast, absolute density, by integration of the thickness of dense tissue at each pixel over the mammogram. Percent VMD is obtained from the ratio absolute VMD divided by breast volume. VMD measures have produced reasonably strong associations with breast cancer risk when validated against visual assessment and computer-assisted methods (11). As VMD methods are becoming increasingly used in epidemiological studies of density (12-18) it becomes important to understand not only how VMD measures are associated to breast cancer risk, but also how they relate to established breast cancer risk factors.

We have much knowledge on the association between breast cancer risk factors and area-based mammographic density measures. Such measures of mammographic density are positively associated with late age at first birth, nulliparity, and postmenopausal hormone therapy (19-22). Alcohol intake has also been positively associated with mammographic density in area-based studies, while physical activity and smoking has been inversely or not associated (23-25). Body mass index (BMI) is strongly inversely associated with percent mammographic density (16), however the association with absolute mammographic density is less clear, with an inverse association mostly reported (6, 16, 26).

To what extent these breast cancer risk factors affect similarly absolute and percent VMD is less clear. There is also less understanding of how the magnitude of VMD differs between women with different risk factor profiles. While a 5% arithmetic difference in percent density in area-based studies is indicative of an effect similar to that of postmenopausal hormone therapy (27), it is not yet clear what represents a “large” effect on VMD.

Area-based measures have shown that mammographic density declines with increasing age and during the menopausal transition (28, 29). It is, however, less clear whether similar age- and menopause-related declines occur with VMD and, if so, which factors may modify the rate of such declines.

We decided to take advantage of a large collection of VMD measures from women participating in BreastScreen Norway to better understand how volumetric and area-based mammographic density measures are correlated, how various risk factors are associated with both percent and absolute VMD, and the extent to which those risk factors modify age- and menopause-related differences.

Materials and methods

Study population

BreastScreen Norway (the Norwegian screening program for breast cancer) is administered by the Cancer Registry of Norway and invites women within a targeted age-range of 50-69 years to a bilateral two-view mammogram biennially. It has a participation rate of about 84% (30). From August 2006 women who underwent mammographic screening were asked to complete a questionnaire on a number of standard breast cancer risk factors and a second questionnaire on current exposures to risk factors. At subsequent screenings they were asked to complete only the second questionnaire (31). Our cohort consisted of women who participated in BreastScreen Norway in the four counties where VMD measures were registered (Hordaland, Rogaland, Akershus, and Trøndelag), who had information on VMD from their first mammographic screening between 2007 and 2014, and had completed both questionnaires (n=63 544). We excluded 1194 women who had a diagnosis of breast cancer or ductal carcinoma in situ (DCIS) previous or up to six months after the screening date, and 622 women who had incomplete data on the VMD variables, leaving information from a total of 61 728 women. Further, we excluded the following due to missing information on the confounding variables BMI (n=6785), education (n=1425), menopausal status (n=1595), and number of pregnancies (n=5689). This left us with 46 234 women for analyses. In analyses of associations between age, menopausal status, and breast cancer risk factors, we excluded pre/perimenopausal women above the age of 55 years, leaving 45 448 women for these analyses.

The study was approved by the Regional Committee for Medical and Health Research Ethics in the South-East Health Region of Norway.

Mammographic density measures

All women in the study had standard two-view (mediolateral oblique and craniocaudal) full-field mammography of each breast with Senographe DS or Senographe Essential machines

(GE Healthcare) in Hordaland and Rogaland, MDM L50 (Philips) in Akershus and MDM L30 (Philips) in Trøndelag. VMD was read using the fully automated system Volpara v1.5.0 (Volpara Health Technologies Limited, Wellington, New Zealand). Volpara is shown to be associated with BI-RADS (i.e. in a study by van der Waal et al., BI-RADS category A [fatty] is equivalent to a median dense volume of 3.6%, category B [scattered density] 5.3%, category C [heterogeneously dense] 10.2%, and category D [extremely dense] 19.3%) (32). Volpara computes the thickness of dense tissue at each individual pixel in the mammogram, using a fatty region as an internal reference. To do the calculation, it is assumed that the pixel value is linearly related to the energy imparted to the x-ray detector, so that the difference in the pixel values between each pixel and the reference point can be related directly to the thickness of dense tissue between the pixel and the x-ray source. Absolute VMD (cm^3) is estimated by integrating the dense thickness at each pixel over the whole mammogram and multiplying by the known pixel size. The total breast volume (cm^3) is derived by multiplying the breast area (cm^2) by breast thickness with a correction for the breast edge. Percent VMD (%) is obtained from the ratio of these two measures (33). In the analyses, we have used the mean VMD from both breasts of the mediolateral oblique view and of the craniocaudal view. Correlation between measures across breasts and views were high, $r > 0.89$, $p < 0.0001$ for percent VMD and $r > 0.82$, $p < 0.0001$ for absolute VMD. The main reason for using the average value across the four images is to reduce random measurement errors and hence to increase precision.

Exposure information

The breast cancer risk factors of interest included reproductive factors (age at menarche, age at first birth, number of pregnancies lasting at least six months, and duration of breastfeeding), menopausal status (whether a woman still had her menstrual period or whether she menstruated regularly, yes=premenopausal, uncertain=perimenopausal, no=postmenopausal), age at menopause (the age at which her menstrual periods stopped), and

hormone use (oral contraceptives and postmenopausal hormone therapy). We also examined self-reported height and BMI (kg/m²) at the time of the mammography, and other risk factors such as education (no education/primary school, high school, university bachelor, university master), current physical activity (no exercise, 1-2.5 hours/week, 2.5-4.5 hours/week, 4.5-6 hours/week, >6 hours/week), alcohol intake (never, 1 glass/week, 2 glasses/week, 3-4 glasses/week, 5-6 glasses/week, >6 glasses/week), and smoking habits (never, past, current). Women with a family history of breast cancer had answered “yes” to the question ‘Have your mother/sister/daughter had breast cancer (yes, no, do not know)’ and/or “yes” to the question ‘Have your grandmother or your mother’s sister had breast cancer (yes, no, do not know)’. Information on current exposures was collected from the questionnaire belonging to the screening round from which we have density measures, and if the questionnaire or certain values were missing, information from the questionnaire completed at a previous screening round was used (approximately 16.5%).

Statistical analyses

We evaluated the agreement by side (left vs right) and view (mediolateral oblique vs craniocaudal) in correlation analyses, calculating Pearson correlation coefficients. We estimated marginal means of percent and absolute VMD associated with the above-mentioned breast cancer risk factors using generalized linear models (GLM) with the post-estimation Stata-command `–margins–` (34), with a normal error distribution and a log link, to account for the skewed distribution of percent and absolute VMD. We further applied robust standard errors to account for additional under- or overdispersion and relax the assumption of log-normality. The delta method was used to calculate 95% confidence intervals (CI) (35). Effects are presented in actual percentage units for percent VMD and in cm³ for absolute VMD, in marginal means as predicted from the model. Based on a priori information from area-based studies, as well as based on trends and effect estimates observed in our analyses, we included the following variables as potential confounders; age at screening, BMI at screening,

education, number of pregnancies, and menopausal status. In additional analyses, we adjusted for age at menarche, age at first birth, duration of breastfeeding in months, use of postmenopausal hormone therapy, and family history of breast cancer. We also mutually adjusted for smoking, alcohol, and physical activity in analyses with those variables. Women with missing information on an exposure variable were excluded from analyses including that variable. Tests for trend were conducted by modelling the exposures as continuous variables.

We estimated differences in percent and absolute VMD per a five-year increment in age at screening in pre/perimenopausal and postmenopausal women separately, overall and by subgroups of breast cancer risk factors. We also included an interaction term of menopausal status and age and tested if interaction was present using the Wald test. If an interaction was present, we estimated means of percent and absolute VMD per a two-year increment in age stratified by the breast cancer risk factor. We examined whether a non-linear model (i.e. cubic spline regression with five degrees of freedom) of VMD with age was a better fit than the linear model and compared the two models using a likelihood-ratio test. Analyses were carried out using Stata version 15 (36).

Results

The characteristics of the women in the study cohort are summarized in Table 1. Their mean age was 56.1 years, and their mean BMI was 25.6 kg/m². 73.5% of the women reported to be postmenopausal, and their mean age at menopause was 49.1 years. 33.5% of the women were ever users of postmenopausal hormone therapy, 79.2% current alcohol consumers, 23.1% current smokers, and 11.5% currently physically inactive. Crude (unadjusted for BMI and other factors) mean percent VMD was 7.2% and absolute VMD 49.3 cm³.

Table 2 shows a strong and inverse association between BMI and percent VMD, with women with BMI < 20 kg/m² having on average a threefold higher percent VMD than those

with BMI > 33 kg/m² (12.9% [95% CI 12.7%–13.2%] versus 3.9% [95% CI 3.9%–4.0%]). In contrast, BMI was positively associated with absolute VMD, with 1.5 times higher VMD in women in the highest, relative to those in the lowest, BMI category (58.4 cm³ [95% CI 57.4 cm³–59.5 cm³] versus 37.9 cm³ [95% CI 37.1 cm³–38.8 cm³]). Both percent and absolute VMD were lower in postmenopausal compared to premenopausal women, and decreased with increasing age. Women who reported a family history of breast cancer had slightly higher percent and absolute VMD than women with no family history.

Table 3 shows mean percent and absolute VMD by age at menarche, age at first birth, age at menopause, education, height and number of pregnancies. We found increasing percent and absolute VMD with increasing age at menarche, increasing age at first birth, increasing age at menopause, and with increasing educational level. Both percent and absolute VMD decreased with increasing number of pregnancies. We observed a weak positive association between height and percent VMD in unadjusted (i.e. adjusted for age only) analyses, but this association diminished upon adjustment for BMI and the other covariates. The positive association between height and absolute VMD, however, persisted after adjustment.

Table 4 shows mean percent and absolute VMD by duration of breastfeeding, age at start of oral contraceptives and duration of oral contraceptives, and use and duration of postmenopausal hormone therapy. We found increasing percent and absolute VMD with increasing duration of breastfeeding, in current postmenopausal hormone therapy users, and with duration of postmenopausal hormone therapy. Neither percent nor absolute VMD were affected by use of oral contraceptives (*p* for trend > 0.38).

Table 5 shows mean percent and absolute VMD by selected lifestyle factors, and both percent and absolute VMD were slightly lower among current smokers. A dose-response positive association was observed between amount of alcohol consumed and percent and absolute VMD. There was an inverse association between physical activity and absolute VMD, and increased percent VMD in women exercising more than six hours a week.

Although most of these associations were highly significant ($p < 0.001$), the magnitude of the effect was modest. We found differences in percent and absolute VMD between the lowest and highest exposure categories (with an absolute magnitude of $\geq 1.0\%$ and $\geq 5.0 \text{ cm}^3$, respectively) for age, BMI, number of pregnancies, menopausal status, and duration of breastfeeding.

The results were essentially unchanged when the analyses were additionally adjusted for age at menarche, age at first birth, duration of breastfeeding in months, use of postmenopausal hormone therapy, and family history of breast cancer. We mutually adjusted for smoking, alcohol, and physical activity in analyses with those variables, and results were unchanged.

When examining the association between age and menopausal status with percent and absolute VMD, we found a larger difference in VMD per five-year increase in age at screening in pre/perimenopausal women compared to postmenopausal women, that this difference was present in women of different risk factor levels, and that this difference was modified by BMI, postmenopausal hormone therapy and family history of breast cancer (Supplementary Table 1).

Figure 1 shows associations between age and menopausal status with VMD, stratified by BMI, postmenopausal hormone therapy and family history of breast cancer. We found the largest difference in percent VMD among postmenopausal women with a $\text{BMI} < 25 \text{ kg/m}^2$ and no apparent difference in postmenopausal women with a $\text{BMI} \geq 30 \text{ kg/m}^2$ ($p\text{-int} < 0.0001$). Associations stratified by use of postmenopausal hormone therapy showed a larger difference in percent and absolute VMD with increasing age at screening in never users of postmenopausal hormone therapy, compared to past and current users ($p\text{-int} < 0.0001$), and associations stratified by a family history of breast cancer showed that premenopausal women with a family history had a larger difference in absolute VMD with age at screening compared to premenopausal women with no family history ($p\text{-int} = 0.054$).

Further examination of VMD with age using cubic spline regression revealed that the non-linear model was not a better fit than the linear model in pre/perimenopausal women (percent VMD $p=0.792$ and absolute VMD $p=0.963$), however there could be a plateauing of VMD in postmenopausal women (percent VMD $p<0.0001$ and absolute VMD $p=0.008$). For these women, the overall VMD-age associations from Supplementary Figure 1 were modestly stronger when we excluded women over 65 years (the coefficient for percent VMD changed from -0.08 to -0.09 and for absolute VMD from -0.03 to -0.04).

Discussion

We found associations between VMD and several breast cancer risk factors in this largely postmenopausal cohort, with the strongest associations between BMI and percent and absolute VMD. BMI was positively associated with absolute VMD, but inversely associated with percent VMD. Further, we found modest differences in percent and absolute VMD between the highest and lowest category of the following risk factors; age, height (only absolute), number of pregnancies, menopausal status, and duration of breastfeeding. Lower percent and absolute VMD were observed with increasing age at screening, and with being postmenopausal compared to pre/perimenopausal. The inverse association with age appears modified not only by menopausal status at baseline, but also by BMI (percent VMD in postmenopausal women), use of postmenopausal hormone therapy, and family history of breast cancer (absolute VMD in premenopausal women).

When comparing the observed associations between VMD and breast cancer risk factors with results from area-based mammographic density studies (12, 17, 37-44), the observed direction of the associations between VMD and breast cancer risk factors were mostly similar. An exception was BMI, which has been inversely associated with

mammographic density in area-based studies. This study found BMI to be inversely associated with percent VMD, but positively associated with absolute VMD, consistent with other studies using volumetric methods (16-18, 45, 46). We have no strong explanation for the difference between volumetric and area-based methods when it comes to BMI except that the two methods capture different variations in breast tissue composition, and that volumetric methods may be more accurate (46).

BMI is associated with breast size and amount of fatty tissue in the breast. It is expected that women with high BMI often have larger breasts and larger amount of fatty tissue, i.e. they have lower percent VMD, however, they also often have more breast tissue in total, and more dense volume, and therefore higher absolute VMD compared to women with smaller breasts (18, 47). It is not clear whether percent or absolute VMD is the most important measure biologically (48), and which measure to use, especially in models including BMI, have implications for the consistency of the estimates. Since BMI is inversely associated with percent VMD, it can reduce the overall effect whenever BMI is positively associated with the exposure, it is therefore important to adjust for BMI especially in analyses with percent VMD.

The underlying distribution of VMD is more left-skewed than the distribution of area-based mammographic density measures, with a smaller range of possible values in VMD. When comparing the differences across categories of age and BMI with a previous area-based study in the same population (41), results suggest that the difference across categories is 2.5-4 times lower for VMD. This implies that a difference of 1.5-2% in VMD is similar to a clinically relevant 5% difference in area-based density. While area-based methods assume that dark areas of a mammogram are composed of fat, and each pixel in the mammogram is either dense or non-dense, volumetric methods estimate the relative amount of dense tissue in each individual pixel. A recent validation study comparing VMD to MRI indicated that Volpara may slightly underestimate the true density as measured by MRI (49). However,

although the associations may be weaker, the overall associations and the usually accepted determinants of mammographic density seems to be similar for VMD.

Breastfeeding is associated with reduced breast cancer risk (50), but not in a case-control study nested within the same screening population as the present study (51). This could be because the protective effect of breastfeeding is time-limited, and may be seen predominately in younger women (52, 53). Consequently, the positive association we observed between breast feeding and VMD should not be given too much significance and may simply reflect the age of our cohort or be a chance finding. Physical activity protects against breast cancer (54), and we found an inverse association between physical activity and absolute VMD. The positive association between percent VMD and exercising more than six hours a week may reflect residual confounding by BMI.

It is well-known that women experience both a reduction in dense tissue and an increase in fatty tissue with increasing age (29). We found lower percent and absolute VMD to be associated with older age at screening in both pre/perimenopausal and postmenopausal women, where the largest age-associated differences were found in pre/perimenopausal women. This may reflect the reduction in circulating sex hormones during the menopausal transition (55). Several risk factors that influence breast cancer and mammographic density could modify this age-VMD association, through modification of breast cell involution or breast tissue composition changes over time (15). We found that the magnitude of the age-related differences in percent VMD was modified by BMI in postmenopausal women, the differences in both percent and absolute VMD by use of postmenopausal hormone therapy, and the difference in absolute VMD by family history of breast cancer in pre/perimenopausal women. The age-associated differences in percent VMD was smaller among postmenopausal women that were overweight and obese than in those with a BMI < 25 kg/m². This finding is consistent with that of Maskarinec et al. (19). Hormonal or reproductive events could be less influential in women with a BMI ≥ 30 kg/m² whose circulating estrogen levels may be

elevated by peripheral conversion in adipose tissue of androgens produced by the supra-renal glands (39). We found larger age-associated differences in VMD in never users of postmenopausal hormone therapy, compared to current and past users, which has been described previously (19, 56). Never users may consist of a unique group of women because they have not experienced menopausal symptoms (57). The larger age-associated difference in absolute VMD by family history of breast cancer in pre/perimenopausal women could perhaps reflect genetic risk factors that are mediated by hormones linked to the menopausal transition (58).

Strengths and limitations

Strengths of our study include detailed information on breast cancer risk factors and VMD measures using a fully automated volumetric method. Another strength is the population-based screening cohort and its very large size, albeit the latter means that differences of small magnitude can reach statistical significance even if they are of no clinical significance. We therefore considered the absolute magnitude of the observed differences.

The most important limitation of the study is that it is cross-sectional rather than longitudinal. The observed age- and menopausal differences may reflect true declines with age and menopausal status, but also differences in density across different cohorts of women, without disentangling between the two. Another limitation is that Volpara tends to underestimate VMD in very dense breasts (49, 59, 60). The selection of internal reference is more complex in dense breasts, i.e. finding an area of the breast that is entirely fat, which affects the calibration of fatty tissue attenuation. This misclassification, which is likely to be non-differential, could have underestimated the magnitude of exposure-VMD associations in our data. Self-reported height and weight measures could lead to misclassification and inability in adjusting completely for the confounding effect of BMI. However, a recent study found that women attending BreastScreen Norway consistently reported weight and height

within one kg/cm (31). The cohort included women between 49 and 71 years of age. A wider age range would have been beneficial, especially the inclusion of women of younger ages.

Conclusions

This large study has added important knowledge concerning VMD; 1) volumetric and area-based mammographic density share similar correlates, 2) the strongest association was found for BMI, with the direction of the association differing for percent (negative association) and absolute (positive association) VMD, 3) percent and absolute VMD were inversely associated with age at screening in both pre/perimenopausal and postmenopausal women; however, larger age-associated differences were observed among pre/perimenopausal women, and 4) the magnitude of the age-associated differences in percent VMD was modified by BMI in postmenopausal women, the differences in both percent and absolute VMD by use of postmenopausal hormone therapy, and the difference in absolute VMD by family history of breast cancer in pre/perimenopausal women. Since VMD methods are becoming widely available in screening and clinical settings, the association between VMD measures and breast cancer risk factors should be investigated further in longitudinal studies.

References

1. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. *J Natl Cancer Inst* 2010; 102: 1224-37
2. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD. Mammographic breast density as an intermediate phenotype for breast cancer. *Lancet Oncol* 2005; 6: 798-808
3. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 1159-69
4. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R. Mammographic features and breast cancer risk: effects with time, age, and menopause status. *J Natl Cancer Inst* 1995; 87: 1622-9
5. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC. Mammographic density and breast cancer in three ethnic groups. *Cancer Epidemiol Biomarkers Prev* 2003; 12: 332-8
6. Haars G, van Noord PA, van Gils CH, Grobbee DE, Peeters PH. Measurements of breast density: no ratio for a ratio. *Cancer Epidemiol Biomarkers Prev* 2005; 14: 2634-40
7. Baglietto L, Krishnan K, Stone J, Apicella C, Southey MC, English DR, Hopper JL, Giles GG. Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. *Am J Epidemiol* 2014; 179: 475-83
8. Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, Vachon C, Bakker MF, Giles GG, Chia KS, Czene K, Eriksson L, Hall P, Hartman M, Warren RM, Hislop G, Chiarelli AM, Hopper JL, Krishnan K, Li J, Li Q, Pagano I, Rosner BA, Wong CS, Scott C, Stone J, Maskarinec G, Boyd NF, van Gils CH, Tamimi RM. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. *J Natl Cancer Inst* 2014; 106:
9. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). *Cancer Causes Control* 1995; 6: 431-8
10. Eberl MM, Fox CH, Edge SB, Carter CA, Mahoney MC. BI-RADS classification for management of abnormal mammograms. *J Am Board Fam Med* 2006; 19: 161-4
11. Eng A, Gallant Z, Shepherd J, McCormack V, Li J, Dowsett M, Vinnicombe S, Allen S, dos-Santos-Silva I. Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods. *Breast Cancer Res* 2014; 16: 439
12. Brand JS, Czene K, Shepherd JA, Leifland K, Heddson B, Sundbom A, Eriksson M, Li J, Humphreys K, Hall P. Automated measurement of volumetric mammographic density: a tool for widespread breast cancer risk assessment. *Cancer Epidemiol Biomarkers Prev* 2014; 23: 1764-72
13. Rajaram N, Mariapun S, Eriksson M, Tapia J, Kwan PY, Ho WK, Harun F, Rahmat K, Czene K, Taib NAM, Hall P, Teo SH. Differences in mammographic density between Asian and Caucasian populations: a comparative analysis. *Breast Cancer Research and Treatment* 2017; 161: 353-62
14. Shepherd JA, Kerlikowske K, Ma L, Duewer F, Fan B, Wang J, Malkov S, Vittinghoff E, Cummings SR. Volume of mammographic density and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2011; 20: 1473-82
15. Hart V, Reeves KW, Sturgeon SR, Reich NG, Sievert LL, Kerlikowske K, Ma L, Shepherd J, Tice JA, Mahmoudzadeh AP, Malkov S, Sprague BL. The effect of change in body mass index on volumetric measures of mammographic density. *Cancer Epidemiol Biomarkers Prev* 2015; 24: 1724-30
16. Lokate M, Kallenberg MG, Karssemeijer N, Van den Bosch MA, Peeters PH, Van Gils CH. Volumetric breast density from full-field digital mammograms and its association with breast cancer risk factors: a comparison with a threshold method. *Cancer Epidemiol Biomarkers Prev* 2010; 19: 3096-105
17. McCormack VA, Highnam R, Perry N, dos Santos Silva I. Comparison of a New and Existing Method of Mammographic Density Measurement: Intramethod Reliability and

- Associations with Known Risk Factors. *Cancer Epidemiology Biomarkers & Prevention* 2007; 16: 1148-54
18. Aitken Z, McCormack VA, Highnam RP, Martin L, Gunasekara A, Melnichouk O, Mawdsley G, Peressotti C, Yaffe M, Boyd NF, dos Santos Silva I. Screen-film mammographic density and breast cancer risk: a comparison of the volumetric standard mammogram form and the interactive threshold measurement methods. *Cancer Epidemiol Biomarkers Prev* 2010; 19: 418-28
 19. Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal investigation of mammographic density: the multiethnic cohort. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 732-9
 20. Reeves KW, Stone RA, Modugno F, Ness RB, Vogel VG, Weissfeld JL, Habel LA, Sternfeld B, Cauley JA. Longitudinal association of anthropometry with mammographic breast density in the Study of Women's Health Across the Nation. *Int J Cancer* 2009; 124: 1169-77
 21. Vachon CM, Pankratz VS, Scott CG, Maloney SD, Ghosh K, Brandt KR, Milanese T, Carston MJ, Sellers TA. Longitudinal trends in mammographic percent density and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 921-8
 22. Gram IT, Funkhouser E, Tabar L. Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women. *Br J Cancer* 1995; 71: 647-50
 23. Brand JS, Czene K, Eriksson L, Trinh T, Bhoo-Pathy N, Hall P, Celebioglu F. Influence of lifestyle factors on mammographic density in postmenopausal women. *PLoS One* 2013; 8: e81876
 24. Qureshi SA, Ellingjord-Dale M, Hofvind S, Wu AH, Ursin G. Physical activity and mammographic density in a cohort of postmenopausal Norwegian women; a cross-sectional study. *Springerplus* 2012; 1: 75
 25. Bremnes Y, Ursin G, Bjurstam N, Gram IT. Different measures of smoking exposure and mammographic density in postmenopausal Norwegian women: a cross-sectional study. *Breast Cancer Res* 2007; 9: R73
 26. Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, Parisky YR, Hamilton AS, Astrahan MA, Mack T. The relative importance of genetics and environment on mammographic density. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 102-12
 27. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. *J Natl Cancer Inst* 2005; 97: 1366-76
 28. Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M. A longitudinal study of the effects of menopause on mammographic features. *Cancer Epidemiol Biomarkers Prev* 2002; 11: 1048-53
 29. Burton A, Maskarinec G, Perez-Gomez B, Vachon C, Miao H, Lajous M, Lopez-Ridaura R, Rice M, Pereira A, Garmendia ML, Tamimi RM, Bertrand K, Kwong A, Ursin G, Lee E, Qureshi SA, Ma H, Vinnicombe S, Moss S, Allen S, Ndumia R, Vinayak S, Teo SH, Mariapun S, Fadzli F, Peplonska B, Bukowska A, Nagata C, Stone J, Hopper J, Giles G, Ozmen V, Aribal ME, Schuz J, Van Gils CH, Wanders JOP, Sirous R, Sirous M, Hipwell J, Kim J, Lee JW, Dickens C, Hartman M, Chia KS, Scott C, Chiarelli AM, Linton L, Pollan M, Flugelman AA, Salem D, Kamal R, Boyd N, Dos-Santos-Silva I, McCormack V. Mammographic density and ageing: A collaborative pooled analysis of cross-sectional data from 22 countries worldwide. *PLoS Med* 2017; 14: e1002335
 30. Hofvind S, Tsuruda K, Mangerud G, Ertzaas AK, Holen ÅS, Pedersen K, Sebuødegård S, Sagstad S, Hestmann CL, Olsen M, Melby W, Lilleborge M, Bhargava S, Moshina N. The Norwegian Breast Cancer Screening Program 1996-2016: Celebrating 20 years of organised mammographic screening. In: *Cancer in Norway 2016 - Cancer incidence, mortality, survival and prevalence in Norway* Oslo: Cancer Registry of Norway, 2017.
 31. Tsuruda KM, Sagstad S, Sebuødegard S, Hofvind S. Validity and reliability of self-reported health indicators among women attending organized mammographic screening. *Scand J Public Health* 2018: 1403494817749393

32. van der Waal D, den Heeten GJ, Pijnappel RM, Schuur KH, Timmers JM, Verbeek AL, Broeders MJ. Comparing Visually Assessed BI-RADS Breast Density and Automated Volumetric Breast Density Software: A Cross-Sectional Study in a Breast Cancer Screening Setting. *PLoS One* 2015; 10: e0136667
33. Highnam R, Brady SM, Yaffe MJ, Karssemeijer N, Harvey J. Robust Breast Composition Measurement - Volpara™. In: Martí J, Oliver A, Freixenet J, Martí R, editors. *Digital Mammography: 10th International Workshop, IWDM 2010, Girona, Catalonia, Spain, June 16-18, 2010 Proceedings*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010. p. 342-9.
34. Mitchell MN. *Interpreting and Visualizing Regression Models Using Stata*. Stata Press: Texas, USA, 2012.
35. Harden J, Hilbe J. *Generalized Linear Models and Extensions*. Third Edition. StataCorp LP, College Station Texas 2012.
36. StataCorp. *Stata Statistical Software: Release 15*. College Station, TX: Statacorp LP2015.
37. Boyd NF, Lockwood GA, Martin LJ, Knight JA, Byng JW, Yaffe MJ, Tritchler DL. Mammographic densities and breast cancer risk. *Breast Dis* 1998; 10: 113-26
38. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. *Breast Cancer Res* 2008; 10: 201
39. Titus-Ernstoff L, Tosteson AN, Kasales C, Weiss J, Goodrich M, Hatch EE, Carney PA. Breast cancer risk factors in relation to breast density (United States). *Cancer Causes Control* 2006; 17: 1281-90
40. El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic breast density by age (United States). *Cancer Causes Control* 2000; 11: 955-63
41. Qureshi SA, Couto E, Hofvind S, Wu AH, Ursin G. Alcohol intake and mammographic density in postmenopausal Norwegian women. *Breast Cancer Res Treat* 2012; 131: 993-1002
42. Ellingjord-Dale M, dos-Santos-Silva I, Grotmol T, Sakhi AK, Hofvind S, Qureshi S, Markussen MS, Couto E, Vos L, Ursin G. Vitamin D intake, month the mammogram was taken and mammographic density in Norwegian women aged 50-69. *PLoS One* 2015; 10: e0123754
43. Couto E, Qureshi SA, Hofvind S, Hilsen M, Aase H, Skaane P, Vatten L, Ursin G. Hormone therapy use and mammographic density in postmenopausal Norwegian women. *Breast Cancer Res Treat* 2012; 132: 297-305
44. Jeffreys M, Warren R, Highnam R, Smith GD. Initial experiences of using an automated volumetric measure of breast density: the standard mammogram form. *The British Journal of Radiology* 2006; 79: 378-82
45. Jeffreys M, Warren R, Highnam R, Davey Smith G. Breast cancer risk factors and a novel measure of volumetric breast density: cross-sectional study. *Br J Cancer* 2008; 98: 210-6
46. Gierach GL, Geller BM, Shepherd JA, Patel DA, Vacek PM, Weaver DL, Chicoine RE, Pfeiffer RM, Fan B, Mahmoudzadeh AP, Wang J, Johnson JM, Herschorn SD, Brinton LA, Sherman ME. Comparison of mammographic density assessed as volumes and areas among women undergoing diagnostic image-guided breast biopsy. *Cancer Epidemiol Biomarkers Prev* 2014; 23: 2338-48
47. Chen Z, Wu AH, Gauderman WJ, Bernstein L, Ma H, Pike MC, Ursin G. Does mammographic density reflect ethnic differences in breast cancer incidence rates? *Am J Epidemiol* 2004; 159: 140-7
48. Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH. Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. *Breast Cancer Res* 2005; 7: R605-8
49. Gubern-Merida A, Kallenberg M, Platel B, Mann RM, Marti R, Karssemeijer N. Volumetric breast density estimation from full-field digital mammograms: a validation study. *PLoS One* 2014; 9: e85952

50. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. *Lancet* 2002; 360: 187-95
51. Ellingjord-Dale M, Vos L, Trelli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. *Breast Cancer Res* 2017; 19: 10
52. Byers T, Graham S, Rzepka T, Marshall J. Lactation and breast cancer. Evidence for a negative association in premenopausal women. *Am J Epidemiol* 1985; 121: 664-74
53. McTiernan A, Thomas DB. Evidence for a protective effect of lactation on risk of breast cancer in young women. Results from a case-control study. *Am J Epidemiol* 1986; 124: 353-8
54. Lynch BM, Neilson HK, Friedenreich CM. Physical activity and breast cancer prevention. *Recent Results Cancer Res* 2011; 186: 13-42
55. Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. *Menopause* 2008; 15: 603-12
56. Sterns EE, Zee B. Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable? *Breast Cancer Res Treat* 2000; 59: 125-32
57. Kelemen LE, Pankratz VS, Sellers TA, Brandt KR, Wang A, Janney C, Fredericksen ZS, Cerhan JR, Vachon CM. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. *Am J Epidemiol* 2008; 167: 1027-36
58. Yaghjian L, Colditz GA, Rosner B, Tamimi RM. Mammographic breast density and breast cancer risk by menopausal status, postmenopausal hormone use and a family history of breast cancer. *Cancer Causes Control* 2012; 23: 785-90
59. van Engeland S, Snoeren PR, Huisman H, Boetes C, Karssemeijer N. Volumetric breast density estimation from full-field digital mammograms. *IEEE Trans Med Imaging* 2006; 25: 273-82
60. Kallenberg MG, van Gils CH, Lokate M, den Heeten GJ, Karssemeijer N. Effect of compression paddle tilt correction on volumetric breast density estimation. *Phys Med Biol* 2012; 57: 5155-68

Table 1 Characteristics of the study population (N=46 234)

Characteristic	Mean (SD), unless stated	Range
Age at mammography, years	56.1 (5.6)	49.1-71.0
Height, cm	166.3 (5.7)	130-198
BMI, kg/m ²	25.6 (4.2)	10.0-54.5
Age at menarche, years	13.3 (1.4)	9-18
Number of pregnancies	2.6 (1.6)	0-20
Age at first birth, years	23.6 (4.6)	13-50
Duration breastfeeding, months	16.9 (12.9)	0-80
Age at menopause, years	49.1 (4.7)	25-67
Age at start of oral contraceptives, years	21.6 (5.2)	11-50
University bachelor/master	36.3%	
Nulliparous	9.3%	
Post-menopausal	73.5%	
Family history of breast cancer	23.3%	
Hormone therapy use ever	33.5%	
Current smokers	23.1%	
Alcohol consumers (≥ 1 glass per week)	79.2%	
Inactive	11.5%	
Mammographic measures		
Percent VMD	7.2 (4.5)	1.5-41.6
Percent VMD, median	5.8	
Absolute VMD cm ³	49.3 (25.2)	5.7-334.9
Absolute VMD cm ³ , median	43.0	
Percent VMD, left CC view	7.5 (4.9)	1.4-51.6
Percent VMD, left CC view, median	5.9	
Percent VMD, left MLO view	6.9 (4.3)	1.1-50.8
Percent VMD, left MLO view, median	5.6	
Absolute VMD, left CC view	46.6 (25.8)	5.1-504.6
Absolute VMD, left CC view, median	40.1	
Absolute VMD, left MLO view	51.6 (28.1)	3.6-464.0
Absolute VMD, left MLO view, median	44.8	

SD, standard deviation; BMI, body mass index, VMD; volumetric mammographic density, CC; craniocaudal, MLO; mediolateral oblique

Table 2 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by selected breast cancer risk factors (n=46 234)

	n	Percent VMD		Absolute VMD	
		Age-adjusted ^a	Multiadjusted ^b (95% CI)	Age-adjusted ^a	Multiadjusted ^b (95% CI)
Age					
<50	1760	9.1	8.2 (8.0-8.4)	56.9	52.5 (51.3-53.8)
50	5365	8.8	8.1 (8.0-8.2)	56.1	52.7 (52.0-53.5)
51	6113	8.2	7.7 (7.6-7.8)	52.8	50.5 (49.9-51.2)
52-53	6880	7.9	7.7 (7.6-7.8)	51.4	50.7 (50.1-51.3)
54-55	4940	7.1	7.2 (7.1-7.3)	48.3	49.2 (48.5-49.8)
56-57	4482	6.7	7.0 (6.9-7.1)	46.5	47.8 (47.2-48.5)
58-59	3777	6.5	6.8 (6.7-6.9)	45.9	47.4 (46.7-48.1)
60-61	3480	6.2	6.5 (6.4-6.7)	45.5	47.1 (46.4-47.9)
62-63	2991	6.0	6.5 (6.4-6.6)	45.1	46.7 (45.9-47.5)
64-65	2591	5.9	6.3 (6.2-6.5)	45.2	47.2 (46.3-48.3)
66-67	2114	5.7	6.1 (6.0-6.3)	44.1	46.5 (45.6-47.4)
≥68	1741	5.7	6.1 (5.9-6.3)	43.1	45.5 (44.6-46.4)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001
BMI (kg/m²)					
<20	2284	13.0	12.9 (12.7-13.2)	38.1	37.9 (37.1-38.8)
20	2583	11.2	11.1 (10.9-11.3)	42.4	42.2 (41.3-43.0)
21	3770	9.8	9.7 (9.6-9.9)	44.4	44.3 (43.5-45.1)
22	4738	8.8	8.8 (8.6-8.9)	46.9	46.9 (46.2-47.6)
23	5038	7.9	7.9 (7.7-8.0)	48.2	48.3 (47.6-49.0)
24	5352	7.2	7.2 (7.1-7.3)	49.2	49.3 (48.6-50.0)
25	4515	6.4	6.4 (6.3-6.5)	50.1	50.3 (49.5-51.0)
26	3863	5.9	5.9 (5.8-6.0)	50.5	50.8 (50.1-51.6)
27	3138	5.6	5.6 (5.5-5.7)	52.9	53.0 (52.1-53.9)
28-30	6270	4.9	4.9 (4.9-5.0)	53.0	52.9 (52.3-53.5)
31-32	2190	4.3	4.3 (4.2-4.4)	54.3	54.3 (53.2-55.3)
≥33	2493	3.9	3.9 (3.9-4.0)	58.9	58.4 (57.4-59.5)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001
Menopausal status					
Pre-	7602	8.3	8.3 (8.2-8.4)	56.1	56.3 (55.6-57.1)
Peri-	4660	7.4	7.6 (7.4-7.7)	51.8	51.5 (50.7-52.3)
Post-	33972	6.9	6.9 (6.9-7.0)	47.2	47.2 (47.0-47.5)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001
Family history of BC					
No	34456	7.2	7.2 (7.1-7.2)	48.8	48.9 (48.6-49.1)
Yes	10447	7.5	7.4 (7.3-7.5)	50.8	50.7 (50.2-51.2)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001

^aAdjusted for age at mammography

^bAdditionally adjusted for BMI, education, menopausal status, and pregnancies

VMD; volumetric mammographic density, CI; confidence interval, sec; secondary, BMI; body mass index, BC; breast cancer

Table 3 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by selected breast cancer risk factors (n=46 234)

	n	Percent VMD		Absolute VMD	
		Age-adjusted ^a	Multiadjusted ^b (95% CI)	Age-adjusted ^a	Multiadjusted ^b (95% CI)
Age at menarche (years)					
9-12	13136	6.7	7.1 (7.0-7.1)	49.0	48.1 (47.7-48.5)
13	12571	7.2	7.2 (7.2-7.3)	49.5	49.4 (49.0-49.9)
14	10844	7.5	7.3 (7.2-7.4)	49.2	49.7 (49.2-50.1)
15-18	7831	7.8	7.4 (7.3-7.5)	49.3	50.2 (49.7-50.8)
<i>p-trend</i>		<0.0001	<0.0001	0.526	<0.0001
Age at first birth^c					
13-20	11380	6.6	6.9 (6.8-7.0)	47.0	47.5 (47.1-48.0)
21-22	7445	6.9	7.0 (7.0-7.1)	47.4	47.9 (47.3-48.4)
23-25	10473	7.3	7.2 (7.2-7.3)	48.7	48.9 (48.4-49.4)
26-30	8395	7.7	7.4 (7.3-7.4)	49.7	49.3 (48.7-49.8)
31-50	3260	7.9	7.5 (7.3-7.6)	53.3	51.2 (50.2-52.1)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001
Age of menopause (years)^d					
<47	7164	6.4	6.5 (6.4-6.6)	45.7	45.4 (44.9-45.9)
47-49	7025	6.7	6.6 (6.5-6.7)	45.5	45.7 (45.2-46.2)
50-52	11658	6.8	6.8 (6.7-6.8)	46.6	46.8 (46.4-47.2)
>52	6393	6.8	6.9 (6.8-7.0)	48.5	48.3 (47.7-48.9)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001
Education					
Lower sec.	9302	6.7	6.9 (6.8-7.0)	47.8	47.9 (47.4-48.4)
Upper sec.	20146	7.0	7.1 (7.0-7.1)	48.9	48.8 (48.5-49.2)
Bachelor	10331	7.7	7.5 (7.4-7.6)	50.2	50.3 (49.8-50.7)
Master	6455	8.1	7.7 (7.6-7.8)	50.7	50.7 (50.1-51.4)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001
Height					
<159	3844	7.0	7.3 (7.2-7.4)	46.7	46.2 (45.4-46.9)
160-164	12934	7.1	7.2 (7.1-7.3)	47.7	47.8 (47.4-48.2)
165-169	15038	7.3	7.2 (7.2-7.3)	49.7	49.8 (49.4-50.2)
170-174	10025	7.4	7.3 (7.2-7.4)	50.7	50.6 (50.1-51.1)
175-179	2945	7.5	7.3 (7.1-7.4)	52.5	52.5 (51.5-53.4)
≥180	524	7.2	7.1 (6.7-7.4)	53.1	52.7 (50.3-55.1)
<i>p-trend</i>		<0.0001	0.707	<0.0001	<0.0001
No of pregnancies					
Never	4287	7.9	8.0 (7.9-8.2)	55.5	55.3 (54.5-56.2)
1	4065	7.6	7.6 (7.5-7.7)	53.3	53.5 (52.6-54.3)
2	17704	7.4	7.3 (7.3-7.4)	49.7	49.8 (49.4-50.2)
3	14251	7.0	7.0 (6.9-7.0)	47.2	47.2 (46.8-47.5)
≥4	5927	6.7	6.8 (6.7-6.9)	45.5	45.3 (44.7-45.8)
<i>p-trend</i>		<0.0001	<0.0001	<0.0001	<0.0001

^a Adjusted for age at mammography

^b Additionally adjusted for BMI, education, menopausal status, and pregnancies

^c Excluding nulliparous women

^d Excluding pre/perimenopausal women

VMD; volumetric mammographic density, CI; confidence interval

Table 4 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by selected breast cancer risk factors (n=46 234)

	n	Percent VMD		Absolute VMD	
		Age-adjusted ^a	Multi-adjusted ^b (95% CI)	Age-adjusted ^a	Multi-Adjusted ^b (95% CI)
Duration breastfeeding (months)					
Parous no breastfeeding	37	6.8	6.2 (5.2-7.2)	44.6	44.3 (40.1-48.6)
1-6	8455	6.9	6.9 (6.8-7.0)	48.1	45.9 (45.3-46.4)
7-12	8996	7.1	7.1 (7.0-7.2)	49.0	47.7 (47.1-48.2)
13-20	8642	7.5	7.4 (7.3-7.5)	49.5	49.2 (48.7-49.7)
21-30	6537	7.5	7.5 (7.4-7.6)	49.7	50.5 (49.8-51.1)
>30	4321	7.5	7.7 (7.5-7.8)	48.4	50.5 (49.7-51.3)
<i>p-trend</i>		<0.0001	<0.0001	0.025	<0.0001
Age at start of OC (years)^c					
<19	6769	7.1	7.2 (7.1-7.3)	49.6	49.2 (48.6-49.8)
19-20	5778	7.4	7.2 (7.1-7.3)	49.5	49.5 (48.8-50.1)
21-24	6118	7.5	7.3 (7.2-7.4)	49.3	49.4 (48.8-50.1)
>24	5179	7.4	7.3 (7.2-7.4)	48.8	48.8 (48.1-49.5)
<i>p-trend</i>		0.001	0.068	0.113	0.395
Duration of OC (years)					
Never users	19855	7.2	7.2 (7.2-7.3)	49.2	49.3 (48.9-49.6)
<2	3498	7.3	7.3 (7.1-7.4)	49.3	49.4 (48.6-50.3)
2-5	8269	7.3	7.3 (7.2-7.4)	49.1	49.2 (48.6-49.7)
6-10	5378	7.3	7.3 (7.2-7.4)	49.6	49.4 (48.7-50.1)
>10	4803	7.4	7.2 (7.1-7.3)	49.1	48.8 (48.1-49.5)
<i>p-trend</i>		0.001	0.916	0.755	0.379
Postmenopausal hormone therapy					
Never	26774	7.2	7.3 (7.2-7.3)	49.7	49.5 (49.2-49.8)
Past	6588	7.1	7.2 (7.1-7.3)	48.5	48.9 (48.3-49.5)
Estrogen current	3986	7.6	7.5 (7.3-7.6)	49.2	49.9 (49.1-50.7)
EP current	2938	8.1	7.8 (7.6-7.9)	52.4	52.4 (51.3-53.4)
<i>p-trend</i>		<0.0001	<0.0001	0.005	<0.0001
Duration of EP therapy (years)					
Never	26774	7.3	7.3 (7.3-7.4)	49.9	49.7 (49.4-50.0)
<3	2629	7.3	7.4 (7.2-7.5)	49.0	49.7 (48.6-50.7)
3-5	2188	7.7	7.6 (7.4-7.7)	50.0	50.5 (49.4-51.6)
6-10	1640	7.8	7.6 (7.4-7.8)	49.3	49.8 (48.6-51.0)
>10	2002	8.2	7.8 (7.6-8.0)	50.5	50.9 (49.7-52.0)
<i>p-trend</i>		<0.0001	<0.0001	0.882	0.061

^aAdjusted for age at mammography

^bAdditionally adjusted for BMI, education, menopausal status, and pregnancies

^cExcluding women who never used oral contraceptives

VMD; volumetric mammographic density, CI; confidence interval, OC; oral contraceptives, EP; estrogen and progestin

Table 5 Unadjusted and adjusted mean (95% CI) percent and absolute VMD by smoking, alcohol use, and physical activity level (n=46 234)

	n	Percent VMD		Absolute VMD	
		Age-adjusted ^a	Multiadjusted ^b (95% CI)	Age-adjusted ^a	Multiadjusted ^b (95% CI)
Smoking					
Never	19780	7.4	7.3 (7.3-7.4)	49.9	49.8 (49.4-50.1)
Former	14741	7.1	7.3 (7.2-7.3)	50.5	49.9 (49.5-50.3)
Current	10377	7.2	7.0 (7.0-7.1)	46.3	47.2 (46.8-47.7)
<i>p-trend</i>		0.055	<0.0001	<0.0001	<0.0001
Alcohol					
Never drinkers	9177	6.9	7.3 (7.2-7.4)	49.1	49.1 (48.5-49.6)
1 glass/week	10929	7.0	7.1 (7.1-7.2)	49.0	48.9 (48.4-49.3)
2 glass/week	8563	7.3	7.2 (7.1-7.3)	48.5	48.8 (48.3-49.3)
3-4 glasses week	10094	7.5	7.3 (7.2-7.4)	49.8	49.8 (49.3-50.3)
5-6 glasses week	3389	7.7	7.3 (7.2-7.5)	50.4	50.2 (49.4-51.1)
>6 glasses week	2072	8.2	7.5 (7.4-7.7)	51.6	51.3 (50.1-52.0)
<i>p-trend</i>		<0.0001	0.001	<0.0001	<0.0001
Physical activity					
No exercise	5266	6.5	7.2 (7.0-7.3)	51.2	50.2 (49.5-50.9)
1-2.5 hours/week	16031	6.9	7.2 (7.1-7.3)	50.1	49.7 (49.4-50.1)
2.5-4.5 hours/week	15281	7.4	7.3 (7.2-7.4)	48.9	49.0 (48.6-49.4)
4.5-6 hours/week	8621	7.8	7.2 (7.2-7.3)	47.5	48.4 (47.9-49.0)
6+ hours/week	664	8.3	7.4 (7.1-7.6)	45.0	46.5 (44.9-48.2)
<i>p-trend</i>		<0.0001	0.074	<0.0001	<0.0001


^aAdjusted for age at mammography

^bAdditionally adjusted for BMI, education, menopausal status, and pregnancies.

VMD; volumetric mammographic density, CI; confidence interval

Figure 1 Associations of percent and absolute volumetric mammographic density with age (in 2-year age groups) and menopausal status, overall and by subgroups. All models are adjusted for body mass index, education, and number of pregnancies. Premenopausal women above the age of 55 years are excluded. Pre, premenopausal and perimenopausal women; post, postmenopausal women; coef, coefficient; p-int, p for interaction. *Rate of decline per a 5-year increment in age. **Interaction between age and the exposure.

Figure 1



Cancer Epidemiology, Biomarkers & Prevention

Volumetric mammographic density, age-related decline, and breast cancer risk factors in a national breast cancer screening program

Kirsti Vik Hjerkind, Merete Ellingjord-Dale, Anna L.V. Johansson, et al.

Cancer Epidemiol Biomarkers Prev Published OnlineFirst June 20, 2018.

Updated version	Access the most recent version of this article at: doi: 10.1158/1055-9965.EPI-18-0151
Supplementary Material	Access the most recent supplemental material at: http://cebp.aacrjournals.org/content/suppl/2018/06/20/1055-9965.EPI-18-0151.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/early/2018/06/20/1055-9965.EPI-18-0151 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.